Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Treasury Shares (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Treasury Shares for 13 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 6.79% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, up 6.79%, and an annual FY2025 reading of $6.6 million, up 6.79% over the prior year.
  • Treasury Shares was $6.6 million for Q4 2025 at Fate Therapeutics, roughly flat from $6.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $7.2 million in Q1 2025 and bottomed at $1.5 million in Q1 2021.
  • Average Treasury Shares over 5 years is $4.7 million, with a median of $4.9 million recorded in 2021.
  • The sharpest move saw Treasury Shares soared 284.99% in 2022, then crashed 47.72% in 2023.
  • Year by year, Treasury Shares stood at $4.0 million in 2021, then surged by 46.25% to $5.9 million in 2022, then plummeted by 47.72% to $3.1 million in 2023, then skyrocketed by 102.74% to $6.2 million in 2024, then rose by 6.79% to $6.6 million in 2025.
  • Business Quant data shows Treasury Shares for FATE at $6.6 million in Q4 2025, $6.6 million in Q3 2025, and $7.0 million in Q2 2025.